This Week's Top 5 User-Curated Stories: NVIDIA's Earnings Report Reignites AI Trading, BTC Treasury Reserves Warm Up Alongside Stablecoins

BlockBeats News, August 28th. This week, the US stock market rebounded strongly in AI earnings and cryptocurrency recovery. As of the August 27th close Eastern Time, the S&P 500 rose by about 0.7% for the week, the Nasdaq rose by about 1.4%, and tech stocks once again became the market focus. Nvidia's earnings exceeding expectations validated the continued strong demand for data centers, driving the recovery in AI chips and computing power sentiment. At the same time, Bitcoin's rebound, coupled with warming regulatory expectations, brought renewed attention to crypto-related stocks such as MSTR, CRCL, PURR. In the healthcare sector, Moderna surged on mRNA cancer vaccine data and approval of the updated version of the COVID-19 vaccine, but commercialization divergence remains.

MSTR (up about 12.04% for the week): Strategy disclosed the sale of approximately $2 billion, did not add more BTC, and established around $15.9 billion in USD Cash; after Bitcoin's rebound, MSTR's leveraged proxy nature re-attracted funds, and the market began to reprice its BTC treasury and cash buffer capacity.

CRCL (up about 7.43% for the week): Bernstein maintained a "Outperform" rating on Circle and a $140 target price, stating that USDC growth does not solely rely on regulatory catalysts; USDC supply expansion, stablecoin payments, and on-chain capital market demand supported transactions, leading to CRCL's oscillating uptrend this week.

PURR (up about 20.58% for the week): The Hyperliquid ecosystem's momentum continued, PURR continued trading the HYPE treasury, regulatory warming, and DeFi beta; the company disclosed about $1.9 billion HYPE holdings, a debt-free balance sheet, surged again on 8/27, highlighting its small-cap high volatility nature.

NVIDIA (up about 9.35% for the week): Q2 revenue of $96.22 billion, Q3 guidance of about $108 billion, data center demand continues to exceed expectations; post-earnings the stock price surged to $227.98, the AI chip theme reignited, also shifting the market focus from "AI capital expenditure peak" concerns to "demand still expanding".

MRNA (up about 2.79% for the week): Melanoma mRNA vaccine data and FDA approval of the new version of the COVID-19 vaccine acted as catalysts, causing the stock price to spike; however, there are still divergences in vaccine applicability, commercialization pace, and profit recovery expectations, leading MRNA to a slight rise after hitting a weekly high and then pulling back.